Antimicrobial Therapeutic Determinants of Outcomes From Septic Shock Among Patients With Cirrhosis

被引:127
作者
Arabi, Yaseen M. [1 ,4 ]
Dara, Saqib I. [1 ]
Memish, Ziad [5 ,6 ]
Al Abdulkareem, Abdulmajeed [2 ]
Tamim, Hani M. [3 ]
Al-Shirawi, Nehad [1 ]
Parrillo, Joseph E. [7 ]
Dodek, Peter [8 ]
Lapinsky, Stephen [9 ]
Feinstein, Daniel [10 ]
Wood, Gordon [11 ]
Dial, Sandra [12 ]
Zanotti, Sergio [13 ]
Kumar, Anand [14 ,15 ,16 ,17 ]
机构
[1] King Saud bin Abdulaziz Univ Hlth Sci, Coll Med, King Abdulaziz Med City, Dept Intens Care, Riyadh 11426, Saudi Arabia
[2] King Saud bin Abdulaziz Univ Hlth Sci, Coll Med, King Abdulaziz Med City, Dept Hepatobiliary Surg & Liver Transplantat, Riyadh 11426, Saudi Arabia
[3] King Saud bin Abdulaziz Univ Hlth Sci, Coll Med, King Abdulaziz Med City, Dept Epidemiol & Biostat, Riyadh 11426, Saudi Arabia
[4] King Abdul Aziz Med City, Dept Resp Serv, Riyadh, Saudi Arabia
[5] Minist Hlth, Dept Infect Dis, Prevent Med Directorate, Riyadh, Saudi Arabia
[6] Alfaisal Univ, Coll Med, Riyadh, Saudi Arabia
[7] Rowan Univ, Cooper Med Sch, Dept Med, Camden, NJ USA
[8] Univ British Columbia, St Pauls Hosp, Vancouver, BC V5Z 1M9, Canada
[9] Univ Toronto, Mt Sinai Hosp, Sect Crit Care Med, Toronto, ON M5G 1X5, Canada
[10] Moses Cone Mem Hosp, Greensboro, NC USA
[11] Univ British Columbia, Victoria Gen Hosp, Royal Jubilee Hosp, Victoria, BC, Canada
[12] McGill Univ, Sect Pulm Med, Montreal, PQ, Canada
[13] Rowan Univ, Cooper Med Sch, Camden, NJ USA
[14] Univ Manitoba, Dept Med Microbiol & Pharmacol Therapeut, Sect Crit Care Med, Winnipeg, MB, Canada
[15] Univ Manitoba, Infect Dis Sect, Hlth Sci Ctr, Winnipeg, MB, Canada
[16] Univ Manitoba, St Boniface Hosp, Winnipeg, MB, Canada
[17] Rowan Univ, Div Cardiovasc Dis & Crit Care Med, Cooper Med Sch, Camden, NJ USA
关键词
SEVERE SEPSIS; ANTIBIOTIC-THERAPY; INFECTIONS; MORTALITY; SURVIVAL; PREDICTORS; GUIDELINES; MANAGEMENT; FAILURE; DISEASE;
D O I
10.1002/hep.25931
中图分类号
R57 [消化系及腹部疾病];
学科分类号
100201 [内科学];
摘要
It is unclear whether practice-related aspects of antimicrobial therapy contribute to the high mortality from septic shock among patients with cirrhosis. We examined the relationship between aspects of initial empiric antimicrobial therapy and mortality in patients with cirrhosis and septic shock. This was a nested cohort study within a large retrospective database of septic shock from 28 medical centers in Canada, the United States, and Saudi Arabia by the Cooperative Antimicrobial Therapy of Septic Shock Database Research Group between 1996 and 2008. We examined the impact of initial empiric antimicrobial therapeutic variables on the hospital mortality of patients with cirrhosis and septic shock. Among 635 patients with cirrhosis and septic shock, the hospital mortality was 75.6%. Inappropriate initial empiric antimicrobial therapy was administered in 155 (24.4%) patients. The median time to appropriate antimicrobial administration was 7.3 hours (interquartile range, 3.2-18.3 hours). The use of inappropriate initial antimicrobials was associated with increased mortality (adjusted odds ratio [aOR], 9.5; 95% confidence interval [CI], 4.3-20.7], as was the delay in appropriate antimicrobials (aOR for each 1 hour increase, 1.1; 95% CI, 1.1-1.2). Among patients with eligible bacterial septic shock, a single rather than two or more appropriate antimicrobials was used in 226 (72.9%) patients and was also associated with higher mortality (aOR, 1.8; 95% CI, 1.0-3.3). These findings were consistent across various clinically relevant subgroups. Conclusion: In patients with cirrhosis and septic shock, inappropriate and delayed appropriate initial empiric antimicrobial therapy is associated with increased mortality. Monotherapy of bacterial septic shock is also associated with increased mortality. The process of selection and implementation of empiric antimicrobial therapy in this high-risk group should be restructured. (HEPATOLOGY 2012;56:2305-2315)
引用
收藏
页码:2305 / 2315
页数:11
相关论文
共 38 条
[1]
American Liver Foundation, LIV LIF CHALL
[2]
Outcome predictors of cirrhosis patients admitted to the intensive care unit [J].
Arabi, Y ;
Ahmed, OAA ;
Haddad, S ;
Aljumah, A ;
Al-Shimemeri, A .
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2004, 16 (03) :333-339
[3]
Efficacy and safety of recombinant human activated protein C for severe sepsis. [J].
Bernard, GR ;
Vincent, JL ;
Laterre, P ;
LaRosa, SP ;
Dhainaut, JF ;
Lopez-Rodriguez, A ;
Steingrub, JS ;
Garber, GE ;
Helterbrand, JD ;
Ely, EW ;
Fisher, CJ .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (10) :699-709
[4]
DEFINITIONS FOR SEPSIS AND ORGAN FAILURE AND GUIDELINES FOR THE USE OF INNOVATIVE THERAPIES IN SEPSIS [J].
BONE, RC ;
BALK, RA ;
CERRA, FB ;
DELLINGER, RP ;
FEIN, AM ;
KNAUS, WA ;
SCHEIN, RMH ;
SIBBALD, WJ .
CHEST, 1992, 101 (06) :1644-1655
[5]
Bacterial infection in patients with advanced cirrhosis:: a multicentre prospective study [J].
Borzio, M ;
Salerno, F ;
Piantoni, L ;
Cazzaniga, M ;
Angeli, P ;
Bissoli, F ;
Boccia, S ;
Colloredo-Mels, G ;
Corigliano, P ;
Fornaciari, G ;
Marenco, G ;
Pistarà, R ;
Salvagnini, M ;
Sangiovanni, A .
DIGESTIVE AND LIVER DISEASE, 2001, 33 (01) :41-48
[6]
Management of sepsis in patients with liver failure [J].
Canabal, Juan M. ;
Kramer, David J. .
CURRENT OPINION IN CRITICAL CARE, 2008, 14 (02) :189-197
[7]
Centers for Disease Control and Prevention, National Hospital Discharge Survey
[8]
Centers for Disease Control and Prevention, CHRON LIV DIS CIRRH
[9]
Infections in patients with end-stage liver disease [J].
Cheruvattath, Rekha ;
Balan, Vijayan .
JOURNAL OF CLINICAL GASTROENTEROLOGY, 2007, 41 (04) :403-411
[10]
Pitfalls in estimating the effect of interventions in the critically ill using observational study designs [J].
Connors, AF .
CRITICAL CARE MEDICINE, 2001, 29 (06) :1283-1284